EP1481633A1 - Verfahren zum Erfassen wenigstens einer Substanz in einem Stoffwechselprozess eines Lebewesens und Gerät zum Durchführen des Verfahrens - Google Patents
Verfahren zum Erfassen wenigstens einer Substanz in einem Stoffwechselprozess eines Lebewesens und Gerät zum Durchführen des Verfahrens Download PDFInfo
- Publication number
- EP1481633A1 EP1481633A1 EP04011103A EP04011103A EP1481633A1 EP 1481633 A1 EP1481633 A1 EP 1481633A1 EP 04011103 A EP04011103 A EP 04011103A EP 04011103 A EP04011103 A EP 04011103A EP 1481633 A1 EP1481633 A1 EP 1481633A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substance
- living
- contrast agent
- metabolism
- unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14556—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases by fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/418—Evaluating particular organs or parts of the immune or lymphatic systems lymph vessels, ducts or nodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6814—Head
- A61B5/6815—Ear
- A61B5/6816—Ear lobe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6814—Head
- A61B5/6815—Ear
- A61B5/6817—Ear canal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
Definitions
- the invention relates to a method for detecting at least a substance in a living being's metabolic process and an apparatus for performing the method.
- an artificial pancreas comprising one on evaluating a physical parameter of Blood based glucose sensor, an insulin reservoir, a Insulin delivery device and a microprocessor as a controller, whereby the glucose sensor quasi continuously the glucose concentration determined in the blood and the insulin delivery device prompted from the insulin reservoir as needed, i.e. depending on the glucose concentration, insulin leave.
- the artificial pancreas is fully implantable or can be arranged externally on the patient, the glucose sensor for example in a patient’s vessel, while insulin is delivered subcutaneously.
- the glucose sensor determines the blood glucose concentration and its dynamics, So the temporal course, quasi continuously and gives this information to the controller.
- An object of the invention is to provide an improved method for detecting at least one substance in a metabolic process of a living being and an associated device create with which, among other things, an elusive Substance is detectable in a living being.
- a molecular, especially biomolecular Contrast agent administered for example in the body of a Living being injected, ingested orally, etc.
- a metabolic building block for example a converting molecule, in particular an enzyme, or a metabolic product, for example a substrate of interest Metabolic chain binds or by means of a biochemical Reaction with this metabolic building block or metabolic product activated in a signaling state becomes.
- metabolic building blocks or Metabolic products are detectable, their direct detection, especially through the skin of the living being is not possible or only with great effort.
- the detector is integrated in a corresponding device, which via a worn on or in the body of the living being for a longer period of time can be.
- the device optionally has means for signal evaluation and / or signal transmission.
- contrast media means molecular engineering highly specific to target molecules, for example Proteins, bind and then using a coupled signaling substance one outside the Body send out measurable signal, so the presence of the target molecules and, if appropriate, their concentration can be.
- Examples of such contrast media are described in US 6,083,486, these consisting of several functional components exist, the alternatives in column 1, line 61 to column 3, line 29 of the US 6,083,486 are listed.
- biomolecular contrast agents in particular fluorescence contrast agents, for optical imaging and use in pharmaceutical research with small animals, for example Mice used. This is primarily the spatial distribution of a target molecule in the body, for example serves to diagnose and localize a tumor.
- contrast agents for example proteins, DNA and / or RNA sections can be detected, which Starting point or reagent of a metabolic process chain are, such contrast media are also suitable, an interested characterize the metabolic process in a highly specific manner.
- Biomolecular contrast agents such as described in the aforementioned US 6,083,486 can also that are constructed between active and inactive protein variants can be distinguished or that the activity of enzymes themselves or of those produced by the enzymes Degradation products can be measured. According to the invention can thus the sales one for one in a highly specific way biological metabolic process characteristic reagent or Degradation product measured and thus on the metabolic rate getting closed.
- the concentration of a molecule from a metabolic chain measurable over a longer period, with which the Questions of medical interest can be answered are whether a certain metabolic process, for example a metabolic process that is characteristic of is a tumor, or a degradation process, for example in the Liver takes place at what intervals, expressed in minutes, hours or days, the metabolic process takes place with what intensity a metabolic process and / or whether the intensity is currently increasing, is decreasing or constant.
- a certain metabolic process for example a metabolic process that is characteristic of is a tumor, or a degradation process, for example in the Liver takes place at what intervals, expressed in minutes, hours or days, the metabolic process takes place with what intensity a metabolic process and / or whether the intensity is currently increasing, is decreasing or constant.
- the contrast medium is being acquired be known that the place where the concentration of the metabolic marker of interest in one there is meaningful concentration.
- concentration of the metabolic marker of interest For example many metabolic markers in detectable concentration transported in the bloodstream and are therefore on measurable at every point in the blood vessel system.
- Other suitable Measurement sites can be located on the body surface directly above body organs, for example the liver, kidney or lymph nodes, or directly over lesions, for example tumors and Surgical wounds, etc.
- a portable place on the body portable device that contains a detector, which the signals emitted by the molecular contrast medium over time, for example as a fluorescence signal, magnetic field or measure radioactive radiation and over time can record.
- the detector must be suitable the wavelength emitted by the fluorescent contrast medium detect. It is used advantageously of an upstream optical filter is selectively detected.
- Figure 1 shows an embodiment of the invention a device 100 for continuously detecting at least one Substance in a living being's metabolic process, the is highlighted by a molecular contrast medium, with a detector unit 110 for detecting the living being administered molecular contrast agent.
- the invention becomes a fluorescent contrast agent is used and, accordingly, is integrated in the device 100 Detector unit 110 for this contrast medium as a detector trained to measure fluorescence signals, comprising for example a CCD chip.
- the contrast agent is designed in such a way that it can be Device 100 integrated enrichment unit 120 in spatial Proximity of the detector unit 110 can be enriched.
- the contrast agent has magnetic properties, for example Includes iron oxide particles
- the enrichment unit 120 one Includes magnets so that the magnetic contrast medium molecules are attracted to the magnet or during transport through the vascular system near the magnet in the blood vessel be partially immobilized.
- the magnet can act as an electromagnet 125 be designed so that the immobilization the molecules can be switched on and off.
- the device 100 further comprises a storage unit 130, in which is the time course of that recorded by the detector unit 110 Measurement signal is saved. Furthermore, at least an interface unit 150 for wireless and / or wired transmission of these signals to a receiver provided for evaluating and / or displaying the signals. In one embodiment, the measurement signal is also without intermediate storage by means of wireless transmission to a receiver transferable.
- the device 100 comprises a display unit 160 for alphanumeric and / or graphic representation of the Strength of the metabolic process and / or to display the Trends in the metabolic process in the sense of increasing, decreasing or constant, an alarm unit 170 that if a preset threshold is exceeded or undershot of the measurement signal becomes active, an input unit 165, for example a keyboard for setting device options or input of data, for example a threshold value, a processor unit 140 for evaluating the measurement data and / or a dosage unit 175 for medication.
- a display unit 160 for alphanumeric and / or graphic representation of the Strength of the metabolic process and / or to display the Trends in the metabolic process in the sense of increasing, decreasing or constant
- an alarm unit 170 that if a preset threshold is exceeded or undershot of the measurement signal becomes active
- an input unit 165 for example a keyboard for setting device options or input of data, for example a threshold value
- a processor unit 140 for evaluating the measurement data and / or a dosage unit 175 for medication.
- At least the detector unit 110 and / or the processor unit 140 prepared in such a way that only the presence or absence of the measurement signal or above the background activity threshold or a background noise measurement signal and based on the presence or absence of the observed metabolic process is closed.
- the Intensity of the measured signal proportional to the concentration the portion of the contrast medium which emphasizes the target molecules, thus the concentration of the target molecule and so that is to the strength of the metabolic process is particular the detector unit 110 for an intensity-sensitive Capture prepared.
- the device 100 is such in one embodiment prepared that a time of administration of the contrast agent entered into the device 100 and stored can at this time when evaluating and, if necessary To be able to consider the representation of the signals.
- the amount of administered Contrast agent can be entered.
- the device 100 further comprises a reservoir unit 185 for the contrast medium and an injection unit 180 for the Contrast agent, by means of which parts of the in the reservoir unit 185 contrast medium in a metered amount Command or at pre-set time intervals in the living being can be injected.
- FIG. 2 shows implementations as exemplary embodiments of the invention of device 100 as on a patient's body wearable devices in training as a bracelet 102 and / or as implant 104.
- the detector unit 110 is integrated into the bracelet 102 in such a way that the detector unit 110 suitably over a Main blood vessel of the wrist is placed.
- FIG. 3 shows exemplary embodiments of the Invention a sectional view in the area of the left ear organ of the patient from FIG. 2 with implementations of the device 100 as ear canal device 106 and ear clip 108.
- the ear canal device 106 constructed in such a way that with the detector unit 110 signals can be recorded from the vascular system of the ear canal are.
- the detector unit 110 is of this type integrated that the detector unit 110 in a more suitable Is placed over the vascular system of the earlobe.
- those include on the body portable device designs 102 to 108 not all at the Figure 1 described units 110 to 185 and / or at least two of the units 110 to 185 are on at least two the device versions 102 to 108 arranged distributed. So can, for example, the detector unit 110 in the ear clip 108 and the display and input unit 160 and 165 in the bracelet 102 can be accommodated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Otolaryngology (AREA)
- Optics & Photonics (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (37)
- Verfahren zum Erfassen wenigstens einer Substanz in einem Stoffwechselprozess eines Lebewesens, wobei ein dem Lebewesen verabreichtes molekulares Kontrastmittel, das die Substanz hervorzuheben vermag, an wenigstens einer Stelle des Lebewesens zeitlich fortlaufend erfasst wird.
- Verfahren nach Anspruch 1, wobei das Kontrastmittel an die Substanz bindet.
- Verfahren nach einem der Ansprüche 1 oder 2, wobei das Kontrastmittel in Verbindung mit der Substanz in einen signalabgebenden Zustand aktiviert wird.
- Verfahren nach einem der Ansprüche 1 bis 3, wobei erfasst wird, ob die Konzentration eines die Substanz hervorhebenden Anteils des Kontrastmittels unter oder über einer vorgebbaren Schwelle liegt.
- Verfahren nach einem der Ansprüche 1 bis 4, wobei eine Größe der Konzentration eines die Substanz hervorhebenden Anteils des Kontrastmittels erfasst wird.
- Verfahren nach einem der Ansprüche 1 bis 5, wobei die Ergebnisse des zeitlich fortlaufenden Erfassens aufgezeichnet werden.
- Verfahren nach einem der Ansprüche 1 bis 6, wobei die Stelle über einem Blutgefäß des Lebewesens liegt.
- Verfahren nach einem der Ansprüche 1 bis 7, wobei die Stelle über einem Organ des Lebewesens liegt.
- Verfahren nach einem der Ansprüche 1 bis 8, wobei die Stelle über einer Läsion des Lebewesens liegt.
- Verfahren nach einem der Ansprüche 1 bis 9, wobei das Kontrastmittel ein optisch detektierbares Kontrastmittel ist.
- Verfahren nach einem der Ansprüche 1 bis 10, wobei das Kontrastmittel ein Fluoreszenzkontrastmittel ist.
- Verfahren nach einem der Ansprüche 1 bis 11, wobei das Kontrastmittel ein über sein Magnetfeld detektierbares Kontrastmittel ist.
- Verfahren nach einem der Ansprüche 1 bis 12, wobei das Kontrastmittel ein über seine radioaktive Strahlung detektierbares Kontrastmittel ist.
- Verfahren nach einem der Ansprüche 1 bis 13, wobei das Lebewesen ein Mensch ist.
- Verfahren nach einem der Ansprüche 1 bis 14, wobei das zeitlich fortlaufende Erfassen ein Erfassen umfasst, das in einer Reihe von zeitlich mit einem vorgebbaren Zeitabstand aufeinanderfolgenden Zeitpunkten durchgeführt wird.
- Verfahren nach Anspruch 15, wobei der Zeitabstand einige Sekunden, Minuten oder Stunden umfasst.
- Verfahren nach einem der Ansprüche 1 bis 16, wobei mittels einem Ergebnis des Erfassens eine Aktivität des Stoffwechsels charakterisiert wird.
- Verfahren nach Anspruch 17, wobei die Aktivität eine Rate des Stoffwechsels, eine als zunehmend, abnehmend oder konstant klassifizierbare Tendenz einer Intensität des Stoffwechsels, eine Zeitdauer von Periodizitätszyklen und/oder eine Häufigkeit, Zeitdauer und/oder einen Zeitabstand eines Auftretens bei einem aperiodisch auftretenden Stoffwechselprozess umfasst.
- Verfahren nach einem der Ansprüche 1 bis 18, wobei aus einem Ergebnis des Erfassens eine Rate des Stoffwechsels als Umsatzmenge in Gewicht oder Volumen der Substanz pro Zeiteinheit mittels eines Models des Stoffwechsels berechnet wird.
- Verfahren nach Anspruch 19, wobei das Model als einzig unbekannten variablen Parameter das Ergebnis des Erfassens neben weiteren bekannten Parametern des Models beinhaltet.
- Gerät zum Durchführen des Verfahrens nach einem der Ansprüche 1 bis 20, wobei das Gerät einen Detektor zum Detektieren eines die Substanz hervorhebenden Anteils des molekularen Kontrastmittels umfasst.
- Gerät nach Anspruch 21, wobei das Gerät als ein am Körper des Lebewesens tragbares Gerät ausgebildet ist.
- Gerät nach einem der Ansprüche 21 oder 22, wobei wenigstens ein Teil des Geräts in ein Armband integriert ist.
- Gerät nach einem der Ansprüche 21 bis 23, wobei wenigstens ein Teil des Geräts in einen Ohrklipp integriert ist.
- Gerät nach einem der Ansprüche 21 bis 24, wobei wenigstens ein Teil des Geräts in den Körper des Lebewesens implantierbar ausgebildet ist.
- Gerät nach einem der Ansprüche 21 bis 25, wobei wenigstens ein Teil des Geräts in einem Gehörgang des Lebewesens tragbar ausgebildet ist.
- Gerät nach einem der Ansprüche 21 bis 26, wobei der Detektor Mittel zum optischen Erfassen eines die Substanz hervorhebenden Anteils des Kontrastmittels umfasst.
- Gerät nach Anspruch 27, wobei die Mittel einen CCD-Chip umfassen.
- Gerät nach einem der Ansprüche 21 bis 28, wobei das Gerät eine alphanumerische und/oder graphische Anzeigeeinheit umfasst.
- Gerät nach einem der Ansprüche 21 bis 29, wobei das Gerät eine Alarmgebereinheit umfasst.
- Gerät nach einem der Ansprüche 21 bis 30, wobei das Gerät eine Eingabeeinheit zum Eingeben von Daten umfasst.
- Gerät nach einem der Ansprüche 21 bis 31, wobei das Gerät eine Dosiereinheit für wenigstens ein Medikament umfasst.
- Gerät nach einem der Ansprüche 21 bis 32, wobei das Gerät eine Injektionseinheit für das Kontrastmittel umfasst.
- Gerät nach einem der Ansprüche 21 bis 33, wobei das Gerät eine Schnittstelleneinheit zum drahtlosen und/oder kabelgebundenen Übertragen von Daten umfasst.
- Gerät nach einem der Ansprüche 21 bis 34, wobei das Gerät Mittel zum Anreichern des Kontrastmittels umfasst.
- Gerät nach Anspruch 35, wobei bei einem magnetisch anreicherbaren Kontrastmittel die Mittel einen wenigstens ein- und ausschaltbar ausgebildeten Magneten umfassen.
- Gerät nach einem der Ansprüche 21 bis 36, wobei das Gerät eine Auswerteeinheit zum Ermitteln einer Aktivität und/oder einer Rate des Stoffwechsels umfasst.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10324600 | 2003-05-30 | ||
DE10324600 | 2003-05-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1481633A1 true EP1481633A1 (de) | 2004-12-01 |
EP1481633B1 EP1481633B1 (de) | 2007-05-02 |
Family
ID=33103653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04011103A Expired - Fee Related EP1481633B1 (de) | 2003-05-30 | 2004-05-10 | Gerät zum Erfassen wenigstens einer Substanz in einem Stoffwechselprozess eines Lebewesens |
Country Status (4)
Country | Link |
---|---|
US (2) | US20050013777A1 (de) |
EP (1) | EP1481633B1 (de) |
JP (1) | JP2004358244A (de) |
DE (1) | DE502004003658D1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2056114A1 (de) * | 2007-10-29 | 2009-05-06 | Koninklijke Philips Electronics N.V. | Automatische Erkennung von Infektionserkrankungen |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4407295A (en) * | 1980-10-16 | 1983-10-04 | Dna Medical, Inc. | Miniature physiological monitor with interchangeable sensors |
EP0770349A1 (de) * | 1995-09-19 | 1997-05-02 | Noboru Akasaka | Gerät zur Patientenüberwachung |
US5628982A (en) * | 1985-05-08 | 1997-05-13 | The General Hospital Corporation | Hydroxy-aryl metal chelates for diagnostic NMR imaging |
US6122536A (en) * | 1995-07-06 | 2000-09-19 | Animas Corporation | Implantable sensor and system for measurement and control of blood constituent levels |
US6149889A (en) * | 1998-03-12 | 2000-11-21 | Department Of Health The Executive Yuan | Radioactive particles and methods for preparing same |
US6207136B1 (en) * | 1997-03-11 | 2001-03-27 | Tokyo University Of Agriculture And Technology | Fluorescent imaging method of saccharide uptake activity of living tissue |
US20020091324A1 (en) * | 1998-04-06 | 2002-07-11 | Nikiforos Kollias | Non-invasive tissue glucose level monitoring |
DE10109539A1 (de) * | 2001-02-28 | 2002-09-12 | Siemens Ag | Vorrichtung zur Untersuchung von Gewebe mit Licht |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5079421A (en) * | 1990-04-19 | 1992-01-07 | Inomet, Inc. | Invasive FTIR blood constituent testing |
US6671540B1 (en) * | 1990-08-10 | 2003-12-30 | Daryl W. Hochman | Methods and systems for detecting abnormal tissue using spectroscopic techniques |
US5408996A (en) * | 1993-03-25 | 1995-04-25 | Salb; Jesse | System and method for localization of malignant tissue |
JPH09122083A (ja) * | 1995-10-30 | 1997-05-13 | Noboru Akasaka | 常時装着可能な患者モニタ装置 |
JPH0975310A (ja) * | 1995-09-19 | 1997-03-25 | Noboru Akasaka | 患者モニタ装置 |
JP2000515778A (ja) * | 1996-07-08 | 2000-11-28 | アニマス コーポレーシヨン | 体液成分レベルの生体内測定および制御のための埋込可能センサーおよびシステム |
US6280703B1 (en) * | 1997-03-13 | 2001-08-28 | Mallinckrodt Inc. | Simultaneous multimodal measurement of physiological function |
US6022526A (en) * | 1997-07-30 | 2000-02-08 | Pharmacyclics, Inc. | Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma |
US6049725A (en) * | 1997-10-15 | 2000-04-11 | Motorola, Inc. | Charging cradle |
US6006119A (en) * | 1998-02-04 | 1999-12-21 | Polestar Technologies, Inc. | Non-invasive optical measurement of blood hematocrit |
US6083486A (en) * | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
US6167297A (en) * | 1999-05-05 | 2000-12-26 | Benaron; David A. | Detecting, localizing, and targeting internal sites in vivo using optical contrast agents |
JP4463404B2 (ja) * | 2000-09-18 | 2010-05-19 | 株式会社島津製作所 | 光測定装置 |
US6597937B2 (en) * | 2001-02-05 | 2003-07-22 | Koninklijke Philips Electronics N.V. | Self-adaptive tracking and phase encoding during data collection for contrast-enhanced MRA and dynamic agent uptake studies |
FR2823969B1 (fr) * | 2001-04-30 | 2003-12-26 | Ge Med Sys Global Tech Co Llc | Procede de prelevement d'un tissu au cours d'un examen par rayons x et dispositif de mise en oeuvre |
WO2004060154A1 (en) * | 2003-01-07 | 2004-07-22 | Intelligent Photonics Control Corp. | Non-invasive blood monitor |
-
2004
- 2004-05-10 EP EP04011103A patent/EP1481633B1/de not_active Expired - Fee Related
- 2004-05-10 DE DE502004003658T patent/DE502004003658D1/de not_active Expired - Lifetime
- 2004-05-27 JP JP2004157548A patent/JP2004358244A/ja active Pending
- 2004-05-28 US US10/855,406 patent/US20050013777A1/en not_active Abandoned
-
2008
- 2008-01-23 US US12/010,246 patent/US20080119699A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4407295A (en) * | 1980-10-16 | 1983-10-04 | Dna Medical, Inc. | Miniature physiological monitor with interchangeable sensors |
US5628982A (en) * | 1985-05-08 | 1997-05-13 | The General Hospital Corporation | Hydroxy-aryl metal chelates for diagnostic NMR imaging |
US6122536A (en) * | 1995-07-06 | 2000-09-19 | Animas Corporation | Implantable sensor and system for measurement and control of blood constituent levels |
EP0770349A1 (de) * | 1995-09-19 | 1997-05-02 | Noboru Akasaka | Gerät zur Patientenüberwachung |
US6207136B1 (en) * | 1997-03-11 | 2001-03-27 | Tokyo University Of Agriculture And Technology | Fluorescent imaging method of saccharide uptake activity of living tissue |
US6149889A (en) * | 1998-03-12 | 2000-11-21 | Department Of Health The Executive Yuan | Radioactive particles and methods for preparing same |
US20020091324A1 (en) * | 1998-04-06 | 2002-07-11 | Nikiforos Kollias | Non-invasive tissue glucose level monitoring |
DE10109539A1 (de) * | 2001-02-28 | 2002-09-12 | Siemens Ag | Vorrichtung zur Untersuchung von Gewebe mit Licht |
Also Published As
Publication number | Publication date |
---|---|
JP2004358244A (ja) | 2004-12-24 |
US20080119699A1 (en) | 2008-05-22 |
EP1481633B1 (de) | 2007-05-02 |
DE502004003658D1 (de) | 2007-06-14 |
US20050013777A1 (en) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69025400T2 (de) | System und verfahren zur prüfung und regelung der blutglukose | |
Griffin et al. | Sacral nerve stimulation increases activation of the primary somatosensory cortex by anal canal stimulation in an experimental model | |
Philipp et al. | Arm movements induced by electrical microstimulation in the superior colliculus of the macaque monkey | |
Cook et al. | Hands-on and hands-off measurement of stress. | |
DD300132A5 (de) | Einrichtung und verfahren zum nachweisen und messen der konzentration von substanzen in einer probe durch optoakustische spektroskopie | |
EP0566710A1 (de) | Medizintechnisches verfahren zur messung der durchblutung eines organs und mittel dazu | |
DE4415896A1 (de) | Analysesystem zur Überwachung der Konzentration eines Analyten im Blut eines Patienten | |
US9744249B2 (en) | Method and apparatus for kidney function analysis | |
DE102005056310A1 (de) | Verfahren und Vorrichtung zur Überwachung von Infusionen | |
EP3010413B1 (de) | Personalisiertes detektionssystem zur erfassung magnetischer objekte im menschlichen organismus | |
Toyomitsu et al. | Neuronal responses of the rat amygdala during extinction and reassociation learning in elementary and configural associative tasks | |
Demertzi et al. | Neural plasticity lessons from disorders of consciousness | |
Ashare et al. | Motivated attention: Incentive effects on attentional modification of prepulse inhibition | |
DE4426694C2 (de) | Vorrichtung zur Langzeitbestimmung des Gehaltes von mindestens einer Substanz in Körperflüssigkeiten | |
Krogsgaard et al. | PV interneurons evoke astrocytic C a2+ responses in awake mice, which contributes to neurovascular coupling | |
Robertson et al. | Exogenous cortisol administration; effects on risk taking behavior, exercise performance, and physiological and neurophysiological responses | |
Tsujimoto et al. | Context-dependent representation of response-outcome in monkey prefrontal neurons | |
EP1481633B1 (de) | Gerät zum Erfassen wenigstens einer Substanz in einem Stoffwechselprozess eines Lebewesens | |
EP2365777B1 (de) | Bestimmung der leberleistung mittels quantitativer messung der metabolisierung von substraten | |
Avula et al. | Improved circuitry and post-processing for interleaved fast-scan cyclic voltammetry and electrophysiology measurements | |
Fetisova et al. | P401 Dynamics of quality of life in children with idiopathic arthritis during etanercept therapy | |
Brazil | Body bionics: how the next generation of biosensors could revolutionise drug delivery | |
EP1364613A1 (de) | Vorrichtung zur Gesundheitsüberprüfung und -überwachung | |
DE8008137U1 (de) | Meßeinrichtung zur fortlaufenden In-vivo-Bestimmung der Konzentration von nichtgasförmigen Stoffwechselprodukten im lebenden, insbesondere menschlichen Körper | |
Hatanaka et al. | Transdural doppler ultrasonography monitors cerebral blood flow changes in relation to motor tasks |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
17P | Request for examination filed |
Effective date: 20050207 |
|
17Q | First examination report despatched |
Effective date: 20050623 |
|
AKX | Designation fees paid |
Designated state(s): DE FR GB IT |
|
RTI1 | Title (correction) |
Free format text: APPARATUS FOR DETECTING A SUBSTANCE OF METABOLISM OF A LIVING BODY |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE FR GB IT |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REF | Corresponds to: |
Ref document number: 502004003658 Country of ref document: DE Date of ref document: 20070614 Kind code of ref document: P |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20070621 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20080205 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20120720 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20130516 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20130528 Year of fee payment: 10 Ref country code: FR Payment date: 20130618 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131203 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 502004003658 Country of ref document: DE Effective date: 20131203 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20140510 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140510 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140602 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140510 |